Review ArticleClinical Review

Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians

Christian Rolfo, Francesco Passiglia, Marcin Ostrowski, Lúcia Farracho, Tereza Ondøichová, Ana Dolcan, Marta Castiglia, Roy Remmen, Konstantinos Papadimitriou and Patrick Pauwels
The Journal of the American Board of Family Medicine January 2015, 28 (1) 124-133; DOI: https://doi.org/10.3122/jabfm.2015.01.140072

References

  1. 1.↵
    Cancer facts & figures 2014. Atlanta (GA): American Cancer Society. Available from: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed May 7, 2014.
  2. 2.↵
    1. Torti D,
    2. Trusolino L
    . Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011;3:623–36.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Bronte G,
    2. Rizzo S,
    3. La Paglia L,
    4. et al
    . Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010;36(Suppl 3):S21–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Ganz PA,
    2. Figlin RA,
    3. Haskell CM,
    4. La Soto N,
    5. Siau J
    . Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 1989;63:1271–8.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Schiller JH,
    2. Harrington D,
    3. Belani CP,
    4. et al
    . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346;92–8.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Scagliotti GV,
    2. Parikh P,
    3. von Pawel J,
    4. et al
    . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–51.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Paz-Ares LG,
    2. de Marinis F,
    3. Dediu M,
    4. et al
    . PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895–902.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Peters S,
    2. Adjei AA,
    3. Gridelli C,
    4. Reck M,
    5. Kerr K,
    6. Felip E
    , ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii56–64.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Mitsudomi T,
    2. Kosaka T,
    3. Endoh H,
    4. et al
    . Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513–20.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Takano T,
    2. Ohe Y,
    3. Sakamoto H,
    4. et al
    . Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829–37.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Han JY,
    2. Park K,
    3. Kim SW,
    4. et al
    . First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Sharma SV,
    2. Bell DW,
    3. Settleman J,
    4. Haber DA
    . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169–81.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Rosell R,
    2. Moran T,
    3. Queralt C,
    4. et al
    ; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–67.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Arrieta O,
    2. Cardona AF,
    3. Federico Bramuglia G,
    4. et al
    . Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 2011;6:1955–9.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Mok TS,
    2. Wu YL,
    3. Thongprasert S,
    4. et al
    . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Bronte G,
    2. Rolfo C,
    3. Giovannetti E,
    4. et al
    . Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol 2014;89:300–13.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Shepherd FA,
    2. Rodrigues Pereira J,
    3. Ciuleanu T,
    4. et al
    ; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Li N,
    2. Yang L,
    3. Ou W,
    4. Zhang L,
    5. Wang SY
    . Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer. PLoS One 2014;9:e102777.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Maemondo M,
    2. Inoue A,
    3. Kobayashi K,
    4. et al
    ; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. TMitsudomi T,
    2. Morita S,
    3. Yatabe Y,
    4. et al
    ; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Zhou C,
    2. Wu YL,
    3. Chen G,
    4. et al
    . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–42.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Rosell R,
    2. Carcereny E,
    3. Gervaise R,
    4. et al
    . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Sequist LV,
    2. Yang JC,
    3. Yamamoto N,
    4. et al
    . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327–34.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Wu YL,
    2. Zhou C,
    3. Hu CP,
    4. et al
    . LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013;31(Suppl):Abstract 8016.
  25. 25.↵
    1. Sequist LV,
    2. von Pawel J,
    3. Garmey EG,
    4. et al
    . Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307–15.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Keedy VL,
    2. Temin S,
    3. Somerfield MR,
    4. et al
    . American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121–7.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Kobayashi S,
    2. Boggon TJ,
    3. Dayaram T,
    4. et al
    . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Janne PA,
    2. Ramalingam S,
    3. Yang JC,
    4. et al
    . Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl): Abstract 8009.
  29. 29.↵
    1. Sequist LV,
    2. Soria JC,
    3. Gadgeel SM,
    4. et al
    . First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014;32(5 Suppl): Abstract 8010.
  30. 30.↵
    1. Engelman JA,
    2. Zejnullahu K,
    3. Mitsudomi T,
    4. et al
    . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–43.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Takezawa K,
    2. Pirazzoli V,
    3. Arcila ME,
    4. et al
    . HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012;2:922–33.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Soda M,
    2. Choi YL,
    3. Enomoto M,
    4. et al
    . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–6.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Shaw AT,
    2. Yeap BY,
    3. Mino-Kenudson M,
    4. et al
    . Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247–53.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Klempner SJ,
    2. Cohen DW,
    3. Costa DB
    . ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J Thorac Oncol 2011;6:1439–40.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Yang P,
    2. Kulig K,
    3. Boland JM,
    4. et al
    . Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90–7.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Lee JO,
    2. Kim TM,
    3. Lee SH,
    4. et al
    . Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011;6:1474–80.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Kwak EL,
    2. Bank YJ,
    3. Camidge DR,
    4. et al
    . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–703.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Camidge DR,
    2. Bang YJ,
    3. Kwak EL,
    4. et al
    . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13:1011–1019.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Kim DK,
    2. Ahn MJ,
    3. Yang P,
    4. et al
    . Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30: (suppl; abstr. 7533) 2012.
  40. 40.↵
    1. Shaw AT,
    2. Kim DW,
    3. Nakagawa K,
    4. et al
    . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385–94.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Mok T,
    2. Kim DW,
    3. Wu JL,
    4. et al
    . First-line crizotinib versus pemetrexed cisplatin or pemetrexed carboplatin in patients with advanced ALK-positive non-squamous non small-cell lung cancer: results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32(5 Suppl); Abstract 8002.
  42. 42.↵
    1. Shaw AT,
    2. Engelman JA
    . Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189–97.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Katayama R,
    2. Shaw AT,
    3. Kahn TM,
    4. et al
    . Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120ra17.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Peréz-Soler R,
    2. Saltz L
    . Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235–46.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Joshi SS,
    2. Ortiz S,
    3. Witherspoon JN,
    4. et al
    . Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116:3916–23.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Boone SL,
    2. Rademaker A,
    3. Liu D,
    4. Pfeiffer C,
    5. Mauro DJ,
    6. Lacouture ME
    . Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152–9.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Busam KJ,
    2. Capodieci P,
    3. Motzer R,
    4. Kiehn T,
    5. Phelan D,
    6. Halpern AC
    . Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169–76.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Lynch TJ Jr.,
    2. Kim ES,
    3. Eaby B,
    4. Garey J,
    5. West DP,
    6. Lacouture ME
    . Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610–21.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Peuvrel L,
    2. Bachmeyer C,
    3. Requiai Z,
    4. et al
    . Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer 2012;20:909–21.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Petrelli F,
    2. Borgonovo K,
    3. Cabiddu M,
    4. Lonati V,
    5. Barni S
    . Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012;78:8–15.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Oxnard GR,
    2. Binder A,
    3. Jänne PA
    . New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013;31:1097–104.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Hammerman PS,
    2. Sos ML,
    3. Ramos AH,
    4. et al
    . Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78–89.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords